This antibody detects LGI1 atcenter. It will recognize only the longer isoform. The antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.
Kreuzreaktivität (Details)
Species reactivity (tested):Human, mouse, rat
Aufreinigung
Peptide affinity chromatography
Immunogen
LGI1 antibody was raised against a 14 amino acid peptide from near the center of human LGI1.
ELISA. Western blot. Immunohistochemistry on paraffin sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
PBS containing 0.02 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.
The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist.Synonyms: Epitempin-1, Leucine-rich glioma-inactivated protein 1